CME Information: CGRP Migraine

Opioid Use Disorder

CME Information: Abuse-Deterrent Formulations

CME Information: Migraine Management

MIGRAINE INSTANT SYMPOSIUM Treatment Choices in Acute Migraine Management: Selecting Appropriate use for Individual Patient     Jointly provided by Primary Care Network and PlatformQ Health Education, LLC ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Primary Care Network and PlatformQ Health Education, LLC. Primary Care Network is accredited by the ACCME to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENTS Live Internet Activity Primary Care Network designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Online On Demand Enduring Material Primary Care Network designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other healthcare professionals will be issued a certificate of participation. Primary Care Network has been awarded Accreditation with Commendation (2013-2019) by the Accreditation Council for Continuing Medical Education (ACCME). DATE OF RELEASE/EXPIRATION Live Activity Friday, January 15, 2016 from 1:00PM – 2:00PM EST. Enduring Material The enduring material will be available from January 15, 2016 – January 15, 2017. ESTIMATED TIME TO COMPLETE THis activity consist of one session, which should take approximately 1.0 hour to complete LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: • Compare and contrast current and emerging formulations for the treatment of acute migraine. • Determine appropriate treatment plan for the management of patients with acute migraine headache, matching patient need with the latest treatment options   TARGET AUDIENCE This activity is intended for primary care clinicians, including those who specialize in internal medicine and family medicine, physician assistants and nurse practitioners involved in care of patients with acute migraine headaches. ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT This activity is supported by an educational grant from Avanir Pharmaceuticals. METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to www.paincarelive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that this module will take approximately 1 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test. HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media. STATEMENT OF DISCLOSURE AND INDEPENDENCE It is the policy of Primary Care Network (PCN) to ensure all of its accredited educational activities are planned, developed, and conducted in accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Essential Areas and Policies. In accordance with ACCME requirements, PCN has Conflict of Interest (COI) and Disclosure Policies that are designed to ensure that PCN accredited educational activities are fair, balanced, independent, evidence based, and based on scientific rigor. PCN’s Resolution of Personal COI Policy aims to ensure that all potential conflicts are identified and resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a PCN accredited Continuing Medical Education (CME) activity are considered Planning Committee Members. Planning Committee Members include individuals involved in a CME activity who may develop, edit, review and/or present content. Planning Committee Members are required to disclose to the participants any real or apparent conflict(s) of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent clinical reviewer. Independence is also monitored through the activity and overall program evaluation process. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Name of Faculty or Presenter Reported Financial Relationship Michael Marmura, MD Consultant: Teva Pharmaceutical Industries Stephen Silberstein, MD Advisory board:Allergan, Inc., Amgen, Lilly, Teva Pharmaceutical Industries Consultant: Allergan, Inc. Amgen, Lilly, Teva Pharmaceutical Industries   The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Name of Planner Reported Financial Relationship Anne Roc, PhD Has nothing to disclose Brian Koffman, MDCM – Primary Care Network CME Content Reviewer Advisory Board: AstraZeneca, Daiichi-Sankyo Research Grants: AbbVie, Janssen Speaker’s Bureau: AstraZeneca, Daiichi-Sankyo Stock Shareholder: AbbVie Spoke as Patient: AbbVie, Janssen The following PCN planner and manager, Jill Hays, hereby state that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. The following PlatformQ Health Education, LLC planner, Shaina Druy, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. STATEMENT OF DISCLOSURE AND INDEPENDENCE: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMERS (if applicable): Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The opinions, ideas, recommendations, and perspectives expressed in this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Primary Care Network, advisory boards or consultants. CONTACT INFORMATION Accreditation Support: Please contact Primary Care Network at http://www.primarycarenetwork.org/.. Technical Support: For any technical issues or issues with your CME Certificate, please contact PainCareLive at 877-394-1306 or at Support@PainCareLive.com.

CME Information: Medication Advancement

The Evolving Spectrum of Antidiabetes Medications:
Practical Perspectives and Clinical Challenges

Jointly provided by Primary Care Network and PlatformQ Health Education, LLC

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Primary Care Network (PCN) and PlatformQ Health Education, LLC. Primary Care Network is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Online Activity
Primary Care Network designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Online On-Demand Enduring Material
Primary Care Network designates each enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other healthcare professionals will be issued a certificate of participation.

Primary Care Network has been awarded Accreditation with Commendation (2013-2019) by the Accreditation Council for Continuing Medical Education (ACCME).

ABIM MOC
The ACCME (Accreditation Council for Continuing Medical Education) and the American Board of Internal Medicine (ABIM) have collaborated to simplify the integration of Maintenance of Certification (MOC) and accredited CME. This collaboration expands the number and diversity of accredited CME activities registered in ABIM’s MOC program, offering ABIM Board Certified physicians more options for receiving MOC points through their participation in CME activities.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Upon completion, your information will be shared with ABIM through Primary Care Network’s ACCME Program and Activity Reporting System (PARS).

DATE OF RELEASE/EXPIRATION
Live Online Activity Thursday October 6, 2016 from 12:00PM – 1:00PM ET.

Enduring Material
The enduring material will be available from October 6, 2016 – October 6, 2017.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

•	Describe how consideration of the pathophysiology of type 2 diabetes, as well as the mechanisms of action of antidiabetes drug classes, can be used to design individualized treatment programs for type 2 diabetes
•	Summarize usage parameters for key newer antidiabetes medications, including indications, contraindications, potential adverse effects, and initiation/titration methodology
•	Discuss assessment of A1C and glycemic patterns as therapeutic targets, and the monitoring for adverse events as a consideration in the advancement of antidiabetes medication therapies

 

TARGET AUDIENCE
This activity is intended for primary care clinicians and clinically-focused diabetologists and endocrinologists, diabetes educators, and other non-MD health care professionals involved in the diagnosis, treatment, education, and management of patients with T2DM, as well as other medical practice support staff who interact with people who have diabetes.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to https://www.diabetesserieslive.com . To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the pre and post-test and activity evaluation. Participants must receive a minimum score of 70% on the post-test in order to receive a certificate.To locate your ABIM ID# please visit: http://www.abim.org/findcadn.apsx.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

STATEMENT OF DISCLOSURE AND INDEPENDENCE
It is the policy of Primary Care Network (PCN) to ensure all of its accredited educational activities are planned, developed, and conducted in accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Essential Areas and Policies. In accordance with ACCME requirements, PCN has Conflict of Interest (COI) and Disclosure Policies that are designed to ensure that PCN accredited educational activities are fair, balanced, independent, evidence based, and based on scientific rigor.

PCN’s Resolution of Personal COI Policy aims to ensure that all potential conflicts are identified and resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a PCN accredited Continuing Medical Education (CME) activity are considered Planning Committee Members. Planning Committee Members include individuals involved in a CME activity who may develop, edit, review and/or present content. Planning Committee Members are required to disclose to the participants any real or apparent conflict(s) of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter	Disclosures:
Richard Beaser, MD	None
Martin J. Abrahamson, MD	Advisory Board: Novo Nordisk
Mark Molitch, MD	Advisory Board: Astra Zeneca, Bristol-Myers Squibb, Janssen Pharmaceuticals, Inc. Consultant: Abbot Laboratories, AbbVie, Janssen Pharmaceuticals, Inc., Lilly, Merck & Co., Novartis Pharmaceuticals Corp, Novo Nordisk, Pfizer, Inc., Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals Industries Research/Grants:Bayer Pharma AG, Novartis Pharmaceuticals Corp, Novo Nordisk Stock Share-holder: Amgen

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner	Reported Financial Relationship
Brian Koffman, MDCM Primary Care Network – CME Content Reviewer	Advisory Board: AstraZeneca, Daiichi-Sankyo Research Grants: AbbVie, Janssen Speaker’s Bureau: AstraZeneca, Daiichi-Sankyo Stock Shareholder: AbbVie Spoke as Patient: AbbVie, Janssen

 

The following PCN planner and manager, Jill Hays, hereby state that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following PlatformQ Health Education, LLC planner, Shaina Druy, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

The opinions, ideas, recommendations, and perspectives expressed in this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Primary Care Network, advisory boards or consultants.

CONTACT INFORMATION
Accreditation Support:
Please contact Primary Care Network at http://www.primarycarenetwork.org/.

Technical Support:
For issues with your CME Certificate, contact DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com

CME Information: SGLT-2

SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes:
Methodology and Monitoring Impact

Jointly provided by Primary Care Network and PlatformQ Health Education, LLC

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Primary Care Network and PlatformQ Health Education, LLC. Primary Care Network is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Online Activity
Primary Care Network designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Online On-Demand Enduring Material
Primary Care Network designates each enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other healthcare professionals will be issued a certificate of participation.

Primary Care Network has been awarded Accreditation with Commendation (2013-2019) by the Accreditation Council for Continuing Medical Education (ACCME).

ABIM MOC
The ACCME (Accreditation Council for Continuing Medical Education) and the American Board of Internal Medicine (ABIM) have collaborated to simplify the integration of Maintenance of Certification (MOC) and accredited CME. This collaboration expands the number and diversity of accredited CME activities registered in ABIM’s MOC program, offering ABIM Board Certified physicians more options for receiving MOC points through their participation in CME activities.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Upon completion, your information will be shared with ABIM through Primary Care Network’s ACCME Program and Activity Reporting System (PARS).

DATE OF RELEASE/EXPIRATION
Live Online Activity Wednesday August 10, 2016 from 11:00AM – 12:00PM ET.

Enduring Material
The enduring material will be available from August 10, 2016 – February 10, 2017.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Session 1:
•	Discuss SGLT-2 physiology especially in the kidney and how it could be targeted as part of the treatment of hyperglycemia in type 2 diabetes
•	Demonstrate the possible integration of SGLT2 inhibitors into a comprehensive glycemic treatment program for type 2 diabetes
•	Identify the risks and benefits of SGLT2 inhibitors to optimally and safety use them, when indicated, to achieve therapeutic goals

TARGET AUDIENCE
This activity is intended for primary care clinicians and other health care providers, such as cardiologists and nephrologists, who provide front-line glycemic management for type 2 diabetes and related conditions.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is not supported by any commercial interest or grantors.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to https://www.diabetesserieslive.com . To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the pre and post-test and activity evaluation. Participants must receive a minimum score of 70% on the post-test in order to receive a certificate.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

STATEMENT OF DISCLOSURE AND INDEPENDENCE
It is the policy of Primary Care Network (PCN) to ensure all of its accredited educational activities are planned, developed, and conducted in accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Essential Areas and Policies. In accordance with ACCME requirements, PCN has Conflict of Interest (COI) and Disclosure Policies that are designed to ensure that PCN accredited educational activities are fair, balanced, independent, evidence based, and based on scientific rigor.

PCN’s Resolution of Personal COI Policy aims to ensure that all potential conflicts are identified and resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a PCN accredited Continuing Medical Education (CME) activity are considered Planning Committee Members. Planning Committee Members include individuals involved in a CME activity who may develop, edit, review and/or present content. Planning Committee Members are required to disclose to the participants any real or apparent conflict(s) of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter	Disclosures:
Richard Beaser, MD	None
Nuha El Sayed, MD	None

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner	Reported Financial Relationship
Jeffrey R. Unger, MD, ABFP, FACE Primary Care Network – CME Content Reviewer	Advisory Board: Abbott, Janssen, Novo Nordisk Consultant: Abbott, Janssen, Novo Nordisk Research Grants: Abbott, Boehringer Ingelheim, Janssen, Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis Speaker’s Bureau: Janssen, Novo Nordisk Stock Shareholder: Novo Nordisk
Curtis P. Schreiber, MD Primary Care Network – CME Content Reviewer	Research Grants: Lilly, Merck Speaker’s Bureau: Avanir

The following PCN planner and manager, Jill Hays, hereby state that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following PlatformQ Health Education, LLC planner, Shaina Druy, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

The opinions, ideas, recommendations, and perspectives expressed in this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Primary Care Network, advisory boards or consultants.

CONTACT INFORMATION
Accreditation Support:
Please contact Primary Care Network at http://www.primarycarenetwork.org/.

Technical Support:
For issues with your CME Certificate, contact DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com

CME Information: Emerging Insulin

The New Insulins are Coming:
What Does This Mean to the Practicing Clinician?

Jointly provided by Primary Care Network and PlatformQ Health Education, LLC

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Primary Care Network and PlatformQ Health Education, LLC. Primary Care Network is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Online Activity
Primary Care Network designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Session 1: Evolving Insulin Options in Type 1 and Type 2 Diabetes
Tuesday, June 14, 2016 from 1:00PM – 2:00PM ET.

Session 2: Leveraging New Insulin Options to Achieve Goals and Ensure Safety
Tuesday, June 14, 2016 from 2:00PM – 3:00PM ET.

Session 3: Case-Based Clinical Application of the New Insulins
Thursday, August 4, 2016 from 10:00AM – 11:00AM ET.

Session 4: Expert Opinion on Diabetes Management with the New Insulins: Submit Your Patient Cases
Thursday, August 4, 2016 from 11:00AM – 12:00PM ET.

Online On-Demand Enduring Material
Primary Care Network designates each enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other healthcare professionals will be issued a certificate of participation.

Primary Care Network has been awarded Accreditation with Commendation (2013-2019) by the Accreditation Council for Continuing Medical Education (ACCME).

ENDURING MATERIALS DATE OF RELEASE/EXPIRATION
Session 1 and 2: The enduring material will be available from June 14, 2016 – February 4, 2017.
Session 3 and 4: The enduring material will be available from August 4, 2016 – February 4, 2017.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Session 1:
•	Identify T2DM patients who would benefit from insulin-based therapy
•	Discuss strategies to overcome patient and clinician barriers to the successful initiation of insulin therapy
•	Differentiate how new and emerging insulins products, including new entities and new modes of administration, differ from previously available insulin products with respect to pharmacokinetic and pharmacodynamic features
Session 2:
•	Apply key, clinically relevant data derived from pivotal trials of new and emerging insulin products
•	Identify the potential place in therapy for new insulins, including how these indications compare to those of the previously available insulins
•	Explain the similarities and differences between a follow-on (biosimilar) insulin and a reference insulin
Session 3:
•	Delineate methods for initiating and titrating new insulin products
•	Explore the potential role for new insulins in helping patients meet diabetes management goals while minimizing adverse effects associated with insulin regimens
Session 4:
•	Apply learnings from previous activities to advance management of your patients using new insulin products
•	Develop insulin regimens that are based on the product’s pharmacodynamic properties and are tailored to the glycemic control needs of the patient

 

TARGET AUDIENCE
This activity is intended for US-based primary care providers, clinical endocrinologists/diabetologists, nephrologists, cardiologists, emergency department specialists, pharmacists, and other clinicians caring for patients with type 2 diabetes.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Novo Nordisk.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to https://www.diabetesserieslive.com . To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the pre and post-test and activity evaluation. Participants must receive a minimum score of 70% on the post-test in order to receive a certificate.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

STATEMENT OF DISCLOSURE AND INDEPENDENCE
It is the policy of Primary Care Network (PCN) to ensure all of its accredited educational activities are planned, developed, and conducted in accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Essential Areas and Policies. In accordance with ACCME requirements, PCN has Conflict of Interest (COI) and Disclosure Policies that are designed to ensure that PCN accredited educational activities are fair, balanced, independent, evidence based, and based on scientific rigor.

PCN’s Resolution of Personal COI Policy aims to ensure that all potential conflicts are identified and resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a PCN accredited Continuing Medical Education (CME) activity are considered Planning Committee Members. Planning Committee Members include individuals involved in a CME activity who may develop, edit, review and/or present content. Planning Committee Members are required to disclose to the participants any real or apparent conflict(s) of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Session 1: Evolving Insulin Options in Type 1 and Type 2 Diabetes

Name of Faculty or Presenter	Disclosures:
Richard Beaser, MD	None
Larry Blonde, MD	Research/Grants: AstraZeneca, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk, and Sanofi Speaker: AstraZeneca, Janssen Pharmaceuticals, Inc., Merck & Co., Novo Nordisk, Sanofi Consultant: AstraZeneca, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, Sanofi
Priscilla Hollander, MD, PhD	Advisory Board: Lilly, Merck & Co., Novo Nordisk Consultant: Merck & Co.

Session 2: Leveraging New Insulin Options to Achieve Goals and Ensure Safety

Name of Faculty or Presenter	Disclosures:
Richard Beaser, MD	None
Anne Peters, MD, CDE	Advisory Board: Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., Lilly, Novo Nordisk Consultant: Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., Lilly, Novo Nordisk Research/Grants: Janssen Pharmaceuticals, Inc.
Alissa Segal, PharmD, CDE, CDTC, FCCP	Advisory Board: Lilly

Session 3: Case-Based Clinical Application of the New Insulins

Name of Faculty or Presenter	Disclosures:
Richard Beaser, MD	None
Mark Stolar, MD	Speaker’s Bureau: AstraZeneca, Takeda Pharmaceuticals
Eugene Wright, MD	Speaker’s Bureau: Abbott Laboratories, Boehringer Ingelheim, Lilly, Voluntis Advisory Board: Abbott Laboratories, Allergan, Inc., Astellas Pharma, Boehringer Ingelheim, Lilly Consultant: Abbott Laboratories, Allergan, Inc., Boehringer Ingelheim Research/Grants: Abbott Laboratories

Session 4: Expert Opinion on Diabetes Management with the New Insulins: Submit Your Patient Cases

Name of Faculty or Presenter	Disclosures:
Richard Beaser, MD	None
Jason Gaglia, M.D., M.M.Sc.	TBD
Peter N Weissman, MD, FACP, FACE	TBD

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner	Reported Financial Relationship
Brian Koffman, MDCM Primary Care Network CME Content Reviewer	Advisory Board: AstraZeneca, Daiichi-Sankyo Research Grants: AbbVie, Janssen Speaker’s Bureau: AstraZeneca, Daiichi-Sankyo Stock Shareholder: AbbVie Spoke as Patient: AbbVie, Janssen

The following PCN planner and manager, Jill Hays, hereby state that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following PlatformQ Health Education, LLC planner, Shaina Druy, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

The opinions, ideas, recommendations, and perspectives expressed in this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Primary Care Network, advisory boards or consultants.

CONTACT INFORMATION
For issues with your CME Certificate, contact DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com

CME Information: Diabetic Retinopathy – CDE

Optimizing Eye Care for People with Diabetes: The Role of Diabetes Educators

 

Presented by the Albert Einstein College of Medicine in Joint Providership with PlatformQ, LLC

ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals Inc.

TUITION
Complimentary

ACCREDITATION STATEMENT

Registered Nurses
The American Association of Diabetes Educators is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational program will provide 1.0 contact hours of continuing education credit.

AADE is accredited as a provider of continuing nursing education by the California Board of Registered Nursing (CEP # 10977).

AADE is an Iowa Board of Nursing approved provider #366. This program provides 1.2 contact hours or 0.12 CEUs (1 contact hour = 50 minutes, or 0.1 CEUs).

Registered Dietitians
The American Association of Diabetes Educators, (AM001) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.0 continuing professional education units (CPEUs) for completion of this program. Continuing Professional Education Provider Accreditation does not constitute endorsement by CDR of a provider, program, or materials.

Registered Pharmacists
The American Association of Diabetes Educators is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 1.0 contact hours (0.10 CEUs) of continuing education credit.

ACPE Universal Program Number:
LIVE activity: 0069-9999-16-051-L01-P
ENDURING activity: 0069-9999-16-051-H01-P
Effective Dates: 5/11/16 – 11/11/16

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The American Association of Diabetes Educators designates this live activity for continuing education credit in the amount of 1.0 CE. Participants should claim only the credit commensurate with the extent of participation in the activity.
Enduring Material
The American Association of Diabetes Educators designates this enduring activity for continuing education credit in the amount of 1.0 CE. Participants should claim only the credit commensurate with the extent of participation in the activity.

DATE OF RELEASE/EXPIRATION
Live Internet Activity
Wednesday, May 11, 2016 at 12:00pm – 1:00pm EDT.

Enduring Material
The enduring material will be available from May 11, 2016 Expiration date: November 11, 2016.

LEARNING OUTCOMES
The purpose of this activity is to enable the learner to summarize the pathophysiology and risk factors for diabetic retinopoathy (DR) and related conditions, apply strategies consistent with guideline recommendations, describe signs and symptoms of treatment-related side-effects requiring urgent management by an ophthalmologist, develop a care plan to identify barriers to regular retinal eye exam and/or treatment, and initiate strategies to overcome the barriers.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

•	Summarize the pathophysiology and risk factors for DR and related conditions
•	Apply strategies consistent with guideline recommendations that include lifestyle changes, regular eye exams, and medical management to improve outcomes for patients with, or at risk for DR
•	List treatment options for DR, and describe signs and symptoms treatment-related side-effects requiring urgent management by an ophthalmologist
•	Develop a care plan that incorporates patient education, and communication to identify barriers to regular retinal eye exam and/or treatment and initiate strategies to overcome the barriers

TARGET AUDIENCE
This activity is intended for certified diabetes educators, including nurses, pharmacists and CDR credentialed practitioners.

ESTIMATED TIME TO COMPLETE
This activity consists of three sessions, each which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.diabetesserieslive.com . To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive credit, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
It is the policy of the American Association of Diabetes Educators to require that anyone who has an opportunity to affect continuing education activities content (e.g. authors, presenters and program planners) with products or services from a commercial interest with which s/he has financial relationships, discloses those financial relationship/s with commercial entities to participants.

Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter	Reported Financial Relationship
Sue McLaughlin, MOL, BS, RD, CDE Staff RD, CDE Children’s Hospital Diabetes & Endocrine Clinic	Consultant: American Diabetes Association Volunteer position: National Certification Board for Diabetes Educators, American Diabetes Association
Jerry Cavallerano, OD, PhD Associate Professor of Ophthalmology, Harvard Medical School	None
Deborah Schlossman, MD Assistant Professor of Ophthalmology, Harvard Medical School	None
Name of Planner	Reported Financial Relationship
Richard Beaser, MD	None
Leslie E. Kolb, MBA, BSN, RN – AADE Nurse Planner	None

The following PlatformQ Health Education, LLC planner, Shaina Druy, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
Please contact the American Association of Diabetes Educators at www.diabeteseducator.org.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com.

For issues with your CME Certificate, contact DiabetesSeriesLive at 877.394.1306 or at Support@DiabetesSeriesLive.com

CME Information: Lung Cancer EGFR

Updates in Lung Cancer: Targeting Epidermal Growth Factor Receptor     ACKNOWLEDGEMENT This educational activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. TUITION Complimentary ACCREDITATION STATEMENT The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENTS Live Internet Activity Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. OTHER CREDITS American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hour of Category 1 credit for completing this program DATE OF RELEASE/EXPIRATION Live Activity Wednesday, September 7, 2016 from 10:00AM EST – 11:00AM EST Enduring Material The enduring material will be available from Wednesday, September 7, 2016 to Tuesday, March 7, 2016. LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: • Review the pathophysiology of NSCLC and the role played by EGFR and activating EGFR mutations • Provide the rationale for EGFR mutation testing to identify appropriate patients for targeted therapy • Evaluate currently approved EGFR inhibitors and their role in the treatment of NSCLC • Discuss the adverse events common to this drug class and how individual drugs might differ, and present management strategies   INTENDED AUDIENCE Oncologists, oncology nurses, nurse practitioners, physician assistants, internists, primary care physicians, pulmonologists, and other health care professionals who treat patients with lung cancer. ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 1 hour to complete. METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that this module will take approximately 1 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test. HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media. FACULTY DISCLOSURE The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present. The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States. Presenters Disclosures Geoffrey R. Oxnard, MD Has nothing to disclose.   Providers Disclosures Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.   Peer Reviewer Disclsoures Rasim A. Gucalp, MD To be posted prior to the live internet activity PlatformQ Health Education, LLC Disclsoures Hamsa Jaganathan, Medical Director Has nothing to disclose relevant to this activity Randi O’Hara, Senior Program Manager Has nothing to disclose relevant to this activity.   DISCLAIMERS (if applicable): The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material. The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, OMedLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. CONTACT INFORMATION Accreditation Support: Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org. Technical Support: For issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com

 

CME Information: Lung Cancer ALK

Updates in Lung Cancer: ALK Inhibition in the Treatment of NSCLC   ACKNOWLEDGEMENT This educational activity is supported by an educational grant from Ariad Pharmaceuticals, Inc. TUITION Complimentary ACCREDITATION STATEMENT The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENTS Live Internet Activity Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. OTHER CREDITS American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hour of Category 1 credit for completing this program DATE OF RELEASE/EXPIRATION Live Activity Wednesday, September 7, 2016 from 11:00AM EST – 12:00PM EST Enduring Material The enduring material will be available from Wednesday, September 7, 2016 to Tuesday, March 7, 2016 LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: • Provide rationale for testing for ALK mutations and use of ALK inhibitors • Evaluate latest clinical data on new and emerging ALK inhibitors and combinations for use in patients with NSCLC • Manage resistance to ALK inhibitors with appropriate second-line options   TARGET AUDIENCE Medical oncologists, radiation oncologists, GI surgeons, GI internists, fellows and other health care professionals (primary care physicians, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with gastric cancer. ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 1 hour to complete. METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that this module will take approximately 1 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test. HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media. FACULTY DISCLOSURE The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present. The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States. Presenters Disclosures Geoffrey R. Oxnard, MD Has nothing to disclose.   Providers Disclosures Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.   Peer Reviewer Disclsoures Rasim A. Gucalp, MD To be posted prior to the live internet activity PlatformQ Health Education, LLC Disclsoures Hamsa Jaganathan, Medical Director Has nothing to disclose relevant to this activity Randi O’Hara, Senior Program Manager Has nothing to disclose relevant to this activity.   DISCLAIMERS (if applicable): The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material. The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, OMedLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. CONTACT INFORMATION Accreditation Support: Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org. Technical Support: For issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com